drugset
drugset / Trial / NCT05588609

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

NCT05588609 ↗

Phase 2 Terminated 13 enrolled Partner Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC

Timeline

Start
2022-11-17
Primary completion
2025-07-03
Completion
2025-07-03

Outcome

Outcome not reported

Stopped: “Merus terminated the study early due to changes in organizational priorities.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Zenocutuzumab Monoclonal antibody 750 mg Intravenous
Background Abiraterone acetate Small molecule 1000 mg Oral
Background Afatinib Small molecule 40 mg Oral
Background Enzalutamide Other / unclassified 160 mg Oral

Indications

castration-resistant prostate carcinoma